Source-grounded facts extracted from Bionano Genomics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Albert A. Luderer was appointed as Interim Chief Executive Officer at Bionano Genomics, Inc..
“As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.”
Erik Holmlin was terminated as President and Chief Executive Officer at Bionano Genomics, Inc..
“On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.”
Mark Adamchak was appointed as Principal Accounting Officer at Bionano Genomics, Inc..
“Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.”
R. Erik Holmlin was appointed as Principal Financial Officer at Bionano Genomics, Inc..
“On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024”
Gülsen Kama departed as Chief Financial Officer at Bionano Genomics, Inc..
“the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.